Publications

Retrouvez les publications de l'Unité de Recherche Translationnelle.

Publications 2022

  • Neron M, Guille A, Allegre L, Colombo PE, Leaha C,  Adelaide J, Carbuccia N, Courtier F, Boissiere F, Crapez E, Fabbro M, Gouy S, Mamessier E, Lambaudie E,Birnbaum D, Bertucci F, Chaffanet M.  Investigation of molecular features involved in clinical responses and survival in advanced endometrial carcinoma treated by hormone therapy. J. Pers. Med. . 2022 Apr 19;12(5):655.  
  • Boissière-Michot F, Mollevi C, Baecker V, Crapez E, Jacot W. In situ hybridization for the assessment of urokinase plasminogen activator and plasminogen activator inhibitor type 1 in formalin fixed paraffin embedded breast cancer specimens. Int J Mol Med. 2022 Jun;49(6):82. 
  • Lopez-Crapez E, Costa L, Tosato G, Ramos J, Mazard T, Guiramand J, Thierry A, Colinge J, Milhiet PE, Bénistant C. Mechanical signatures of human colon cancers. Sci Rep 2022 12, 12475. 
  • Ferey J, Larroque M, Schmitz-Afonso I, Le Maître J, Sgarbura O, Carrere S, Quenet F, Bouyssiere B, Enjalbal C, Mounicou S, Afonso C.Imaging Matrix-Assisted Laser Desorption/Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry of oxaliplatin derivatives in human tissue sections. Talanta. 2022 Jan 15;237:122915. 
  • Ychou M, Rivoire M, Thezenas S, Guimbaud R, Ghiringhelli F,Mercier-Blas A, Mineur L, Francois E, Khemissa F, Chauvenet M, Kianmanesh R, Fonck M, Houyau P, Aparicio T, Galais MP, Audemar F,  Assenat E,  Lopez-Crapez E, Jouffroy C, Adenis A, Adam R, Bouché O. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. Br J Cancer. 2022 Jan 6. 
  • Publications 2021
    • Boissière-Michot F, Jacot W, Massol O, Mollevi C, Lazennec G. CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers. Cancers 2021, 13, 2328. 
    • Alcaraz LB, Mallavialle A, David T, Derocq D, Delolme F, Dieryckx C, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Du Manoir S, Huesgen PF, Overall C M, Tartare-Deckert S, Jacot W, Chardès T, Guiu S, Roger P, Reinheckel T, Moali C, Liaudet-Coopman E. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. Theranostics 2021, 11(13), 6173–6192. 
    • Larroque M, Mounicou S, Sgarbura O, Arnaudguilhem C, Rebel L, Leaha C, Faye PA, Enjalbal C, Quénet F, Bouyssiere B, Carrere S. Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging. Pleura Peritoneum. 2021 Mar 24;6(2):67-74.
    • Palassin P, Lapierre M, Pyrdziak S, Wagner A, Stehle R, Corsini C, Duffour J, Bonnet S, Boulahtouf A, Rodriguez C, Ho-Pun-Cheung A, Lopez-Crapez E, Boissière-Michot F, Bibeau F, Thezenas S, Elarouci N, Selves J, Hoffmann JS, Roepman P, Mazard T, Buhard O, Duval A, Jalaguier S, Cavaillès V, Castet-Nicolas A. A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors. Cancers (Basel). 2021 Sep 3;13(17):4449. 
    • Jacot W, Maran-Gonzalez A , Massol O, Sorbs C, Mollevi C, Guiu S, Boissière-Michot F, Ramos  J. Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers. Cancers 2021, 13, 6059. 
    • Larroque M, Arnaudguilhem C, Bouyssiere B, Quenet F, Bouazza N, Jarlier M, Boulabas S, Mounicou S, Sgarbura O.
      Evaluation of the environmental contamination and exposure risk in medical/non-medical staff after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy. Toxicol Appl Pharmacol. 2021 Oct 15;429:115694. 
    • Relier S, Ripoll J, Guillorit H, Amalric A, Achour C, Boissière F, Vialaret J, Attina A, Debart F, Choquet A, Macari F, Marchand V,  Motorin Y, Samalin E, Vasseur JJ, Pannequin J, Aguilo F, Lopez-Crapez E, Hirtz C,  Rivals E,  Bastide A, David A. FTO-mediated cytoplasmic m 6 A m demethylation adjusts stem-like properties in colorectal cancer cell. Nat Commun 2021 Mar 19;12(1):1716.
    • Kantar D, Bousquet Mur E, Mancini M, Slaninova V, Ben Salah Y, Costa L, Forest E, Lassus P, Géminard C, Boissière-Michot F, Orsetti B, Theillet C, Colinge J, Benistant C, Maraver A, Heron-Milhavet L, Djiane A. MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis. Sci Rep 2021 Mar 11;11(1):5752.
    • Assenat E, Mineur L, Mollevi C, Lopez-Crapez E, Lombard-Bohas C, Samalin E, Portales F, Walter T, de Forges H,  Dupuy M, Boissière-Michot F, Ho-Pun-Cheung A, Ychou M, Mazard T. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as 1st-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). Int. J. Cancer. 2021;148:682–691.
    • Arnaudguilhem C, Larroque M, Sgarbura O, Michau D, Quenet F, Carrère S, Bouyssière B. Toward a comprehensive study for multielemental quantitative LA-ICP MS bioimaging in soft tissues. Talanta. 2021;222:121537.
    • Boissière‐Michot F, Chabab G, Mollevi C, Guiu, S, Lopez‐Crapez E, Bonnefoy N, Lafont V, Jacot W. Clinicopathological Correlates of γδ T Cell Infiltration in Triple‐Negative Breast Cancer. Cancers 2021, 13, 765. 

     

  • Publications 2020
    • Guo Y, Gabola M, Lattanzio R, Paul C, Pinet V, Tang R, Turali H, Bremond J, Longobardi C, Maurizy C, Da Costa Q, Finetti P, Boissière-Michot F, Rivière B, Lemmers C, Garnier S, Bertucci F, Zlobec I, Chebli K, Tazi J, Azar R, Blanchard JM, Sicinski P, Mamessier E, Lemmers B, Hahne M. Cyclin A2 maintains colon homeostasis and is a prognostic factor in CRC. J Clin Invest. 2020 Dec 17:131517.
    • Hamyeh M, Bernex F, Larive RM, Naldi A, Urbach S, Simony-Lafontaine J, Puech C, Bakhache W, Solassol J, Coopman PJ, Hendriks WJAJ, Freiss G. PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness. Theranostics. 2020;10(3):1016-1032.
    • Samalin E, de la Fouchardière C, Thézenas S, Boige V,  Senellart H, Guimbaud R, Taïeb J, François E, Galais MP, Lièvre A, Seitz JF, Metge JP, Bouché O, Boissière F, Lopez-Crapez E, Bibeau F, Ho Pun Cheung  A, Ychou M , Adenis A, Di Fiore F,  Mazard T. Sorafenib plus irinotecan combination in patients with  RAS-mutated metastatic colorectal cancer refractory to standard combined chemotherapies: A multicenter, randomized phase 2 trial (NEXIRI-2/PRODIGE 27) . Clin Colorectal Cancer 2020.
    • Bourillon L, Demontoy S, Lenglet A, Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H, Rathat G, Garambois V, Bonnefoy N, Michaud HA, Chardès T, Tosi D, Pelegrin A, Azria D, Larbouret C,  Bourgier C. Higher anti-tumor efficacy of the dual HER3-EGFR antibody MEHD7945A combined with ionizing irradiation in cervical cancer cells. Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):1039-1051.
    • Jacot W, Mazel M, Mollevi C, Pouderoux S, D’Hondt V, Cayrefourcq L, Bourgier C, Boissiere-Michot F, Berrabah F,  Crapez E, Bidard FC, Viala M, Maudelonde T, Guiu S, Alix-Panabieres C. Clinical correlations of PD-L1 status in liquid and standard biopsies in breast cancer. Clin Chem 2020.
    • Chabab G, Barjon C, Abdellaoui N, Salvador-Prince L, Dejou C, Michaud HA, Boissière-Michot F, Lopez-Crapez E, Jacot W, Pourquier D, Bonnefoy N, Lafont V. Identification of a regulatory Vd1 gamma delta T cell subpopulation expressing CD73 in human breast cancer.  J Leukoc Biol. 2020 Jun;107(6):1057-1067. 
    • Mansouri H, Alcaraz L, Mollevi C, Mallavialle A, Jacot W, Boissière-Michot F, Simony-Lafontaine J, Laurent-Matha V, Roger P, Liaudet-Coopman E, Guiu S. Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. Cancers 2020, 12, 1244.
    • Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S. BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple- Negative Breast Cancer. Cancers 2020, 12, 828.
    • Dadouch M, Ladner Y, Bich C, Larroque M, Larroque C, Morel J, Bonnet P-A, Perrin C. An in-line enzymatic microreactor for the middle-up analysis of monoclonal antibodies by capillary electrophoresis.Analyst. 2020 Mar 7;145(5):1759-1767 
    • Basbous J, Aze A, Chaloin L, Lebdy R, Hodroj D, Ribeyre C, Larroque M, Shepard C, Kim B, Pruvost A, Moreaux J, Maiorano D, Mechali M, Constantinou A. Dihydropyrimidinase Protects From DNA Replication Stress Caused by Cytotoxic Metabolites. Nucleic Acids Res. 2020 Feb 28;48(4):1886-1904.
    • Boissière-Michot F, Jacot W, Fraisse J, Gourgou S, Timaxian C, Lazennec G. Prognostic Value of CXCR2 in Breast Cancer. Cancers (Basel). 2020 Jul 27;12(8):E2076.

    • Chabab G, Boissière-Michot F, Mollevi C, Ramos J, Lopez-Crapez E, Colombo PE, Jacot W, Bonnefoy N, Lafont V. Diversity of tumor-infiltrating γδ T cell abundance in solid cancers ; Cells. 2020 Jun 24;9(6):E1537. 

  • Publications 2019
    • Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E, De Forges H, Firmin N, Guiu S, Jacot W, Lehmann S. The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer. 2019 Jan 30;19(1):110.
    •  Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.J Immunother Cancer. 2019 Feb 4;7(1):29.
    • Jacot W, Dalenc F, Lopez-Crapez E, Chaltiel L, Durigova A, Gros N, Lozano N, Lacaze JL, Pouderoux S, Gladieff L, Romieu G, Roché H, Filleron T, Lamy PJ.  PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. Breast Cancer Res Treat. 2019 Jul 11.
    • Toufic Kassouf, Romain Maxime Larive, Anne Morel, Serge Urbach, Nadir Bettache, Ma Cleofas Marcial Medina, Fabrice Mèrezègue, Gilles Freiss, Marion Peter, Florence Boissière-Michot, Jérôme Solassol, Philippe Montcourrier and Peter Coopman. The Syk Kinase Promotes Mammary Epithelial Integrity and Inhibits Breast Cancer Invasion by Stabilizing the E-Cadherin/Catenin Complex, Cancers 2019, 11, 1974.
    • Ho-Pun-Cheung A, Bazin H, Boissière-Michot F, Mollevi C, Simony-Lafontaine J, Landas E, Bleuse JP, Chardès T, Prost JF, Pèlegrin A, Jacot W, Mathis G, Lopez-Crapez E. Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples. Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples.Br J Cancer. 2019 Dec 3.
    • Béganton B, Solassol I, Mangé A, Solassol J. Protein interactions study through proximity-labeling. Expert Rev Proteomics.2019 Aug;16(8):717-726
    • Solassol I, Pinguet F, Quantin X. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management.Biomolecules. 2019 Oct 30;9(11).
  • Publications 2018
    • Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy PJ, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W. Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Br J Cancer. 2018 Jun 8.
    • Kumbhar R, Vidal-Eychenie S, Georgios Kontopoulos D, Larroque M, Larroque C,  Basbous  J, Kossida S, Ribeyre C, Constantinou A. Recruitment of ubiquitin-activating enzyme UBA1 to DNA bypoly(ADP-ribose) promotes ATR signalling. Life Sci Alliance. 2018 Jun 21;1(3):e201800096.
  • Publications 2017
    • Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol. 2017 Sep 1;28(9):2149-2159.
    • Arsic N, Ho-Pun-Cheung A, Lopez-Crapez E, Assenat E, Jarlier M, Anguille C, Colard M, Pezet M, Roux P, Gadea G. The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner. PLoS One. 2017 Apr 6;12(4):e0175607.
    • D’Hondt V, Lacroix-Triki M, Jarlier M, Boissière-Michot F, Puech C, Coopman P, Katsaros D, Freiss G. High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome. Oncotarget 2017 Sep 21;8(56):95662-95673.
    • They L, Michaud HA, Becquart O, Lafont V, Guillot B, Boissière-Michot F, Jarlier M, Mollevi C, Eliaou JF,  Bonnefoy N, Gros L. PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody, Oncoimmunology 2017 Jul 20;6(10):e1353857.
    • Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M. Antibody targeting of claudin-1 as a potential colorectal cancer therapy. J Exp Clin Cancer Res. 2017 Jun 28;36(1):89.
    • Belguise K, Cherradi S, Sarr A, Boissière F, Boulle N, Simony-Lafontaine J, Choesmel-Cadamuro V, Wang X, Chalbos D. PKCθ-induced phosphorylations control the ability of Fra-1 to stimulate gene expression and cancer cell migration. Cancer Letters 2017 Jan 28;385:97-107.
  • Publications 2016
    • Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thézenas S, Jacot W. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? Int J Cancer. 2016 Nov 15;139(10):2299-311.
    • Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thezenas S, Jacot W. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer. 2016 Jul 7;16:428.
    • El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, Mazard T, Pezet D, Mathonnet M, Ychou M, Thierry AR. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clin Cancer Res. 2016 Jun 15;22(12):3067-77.
    • Boissière-Michot F, Frugier H, Ho-Pun-Cheung A, Lopez-Crapez E, Duffour J, Bibeau F. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome related) microsatellite instable colorectal carcinomas Virchows Arch. 2016 469(2), 135-144.
    • Chevalier C, Collin G, Descamps S, Touaituhuata H, Simon V, Reymond N, Fernandez L, Milhiet PE, Georget V, Urbach S, Lasorsa L, Orsetti B, Boissière-Michot F, Lopez-Crapez E, Theillet C, Roche S, Benistant C. TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion. Nat Commun. 2016 Feb 22;7:10765
    • Duffour J, Combes A, Crapez E, Boissière-Michot F, Bibeau F, Senesse P, Ychou M, Courraud J, de Forges H, Roca L. Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options. J Genet Couns. 2016 Jun;25(3):432-42.
  • Publications 2015
    • Lopez-Crapez E, Ho-Pun-Cheung A, Garnero P, Bazin H. Evaluation of the dimerization profiles of HER tyrosine kinases by time-resolved Förster resonance energy transfer (TR-FRET). Methods Mol Biol. 2015;1233:45-55.
    • Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial. Oncotarget. 2015 May 20;6(14):12796-808.
    • Colombo PE, du Manoir S, Orsetti B, Bras-Gonçalves R, Lambros MB, MacKay A, Nguyen TT, Boissière F, Pourquier D, Bibeau F, Reis-Filho JS, Theillet C. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. Oncotarget. 2015 Sep 29;6(29):28327-40.
    • Jacot W, Mollevi C, Fina F, Lopez-Crapez E, Martin PM, Colombo PE, Bibeau F, Romieu G, Lamy PJ. High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. BMC Cancer. 2015 Dec 18;15:986. doi: 10.1186/s12885-015-1977-3.
  • Publications 2014
    • Boissière-Michot F, Lazennec G, Frugier H, Jarlier M, Roca L, Duffour J, Du Paty E, Laune D, Blanchard F, Le Pessot F, et al. (2014). Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. OncoImmunology 3:e29256. eCollection 2014.
    • Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T. (2014). Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer. 110(5):1148-54.​
    • Rouanet P, Roger P, Rousseau E, Thibault S, Romieu G, Mathieu A, Cretin J, Barneon G, Granier M, Maran-Gonzalez A, Daures JP, Boissière-Michot F, Bibeau F. (2014). HER2 overexpression a major risk factor for recurrence in pT1a-bN0 breast cancer: results from a French regional cohort. Cancer Med. 3(1):134-42.
    • du Manoir S, Orsetti B, Bras-Gonçalves R, Nguyen T, Lasorsa L, Boissière F, Massemin B,  Colombo PE, Bibeau F, Jacot W, Theillet C. (2014). Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Mol Oncol.  8(2):431-43
    • Bianga J, Bouslimani A, Bec N, Quenet F,  Mounicou S, Bouyssiere B, Lobinski R,  Szpunar  J, Larroque C. (2014). Complementarity of MALDI and LA ICP mass spectrometry for platinum anticancer imaging in human tumor. Metallomics, May 2014.
    • Lafaille F, Solassol I, Enjalbal C, Bertrand B, Doulain PE, Vappiani J, Bonnet PA, Deleuze-Masquéfa C, Bressolle FM. Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2014 Jan;88:429-40.
    • Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014 Apr;20(4):430-5.
arrow-leftarrow-rightchevron-downchevron-leftchevron-rightchevron-upchevrons-leftchevrons-rightdirectory-placeholderexternal-linkfacebookfooter-bgicon-accounticon-annuaireicon-contrasted-officon-contrasted-onicon-donationicon-downloadicon-mailinstagramlinkedinlogo-choositmore-verticalplaysearchshare-2twitterviadeoxyoutube